| scholarly article | Q13442814 |
| P356 | DOI | 10.1002/BIMJ.200510232 |
| P698 | PubMed publication ID | 16972714 |
| P5875 | ResearchGate publication ID | 6817807 |
| P894 | zbMATH Open document ID | 1442.62289 |
| P50 | author | Frank Bretz | Q64516310 |
| Franz König | Q40096364 | ||
| P2093 | author name string | Heinz Schmidli | |
| Willi Maurer | |||
| Amy Racine | |||
| P433 | issue | 4 | |
| P921 | main subject | hypothesis | Q41719 |
| phase III clinical trial | Q42824827 | ||
| phase II clinical trial | Q42824440 | ||
| P6104 | maintained by WikiProject | WikiProject Mathematics | Q8487137 |
| P304 | page(s) | 623-634 | |
| P577 | publication date | 2006-08-01 | |
| P1433 | published in | Biometrical Journal | Q15720842 |
| P1476 | title | Confirmatory seamless phase II/III clinical trials with hypotheses selection at interim: general concepts | |
| P478 | volume | 48 |
| Q40109131 | A Hybrid Geometric Phase II/III Clinical Trial Design based on Treatment Failure Time and Toxicity |
| Q38156680 | A comparison of methods for constructing confidence intervals after phase II/III clinical trials |
| Q42130183 | A comparison of methods for treatment selection in seamless phase II/III clinical trials incorporating information on short-term endpoints |
| Q46406244 | A conditional error function approach for subgroup selection in adaptive clinical trials |
| Q37236599 | A dose-ranging study of tiotropium delivered via Respimat Soft Mist Inhaler or HandiHaler in COPD patients. |
| Q94581117 | A model-based approach for simulating adaptive clinical studies with surrogate endpoints used for interim decision-making |
| Q39708750 | A modified varying-stage adaptive phase II/III clinical trial design |
| Q42322419 | A multi-stage drop-the-losers design for multi-arm clinical trials. |
| Q88887124 | A nonparametric Bayesian basket trial design |
| Q57430578 | A novel adaptive design strategy increases the efficiency of clinical trials in secondary progressive multiple sclerosis |
| Q45342085 | A seamless phase II/III design with sample-size re-estimation. |
| Q40009132 | A simple and flexible graphical approach for adaptive group-sequential clinical trials |
| Q44494327 | A varying-stage adaptive phase II/III clinical trial design |
| Q48194413 | Accurate p-values for adaptive designs with binary endpoints |
| Q52690719 | Adaptive Clinical Trials: Advantages and Disadvantages of Various Adaptive Design Elements. |
| Q44711945 | Adaptive Methods: Telling “The Rest of the Story” |
| Q36264856 | Adaptive design of confirmatory trials: Advances and challenges |
| Q59336746 | Adaptive designs in clinical trials: from scientific advice to marketing authorisation to the European Medicine Agency |
| Q37008670 | Adaptive seamless designs: selection and prospective testing of hypotheses |
| Q35565672 | Advances in Statistical Approaches Oncology Drug Development |
| Q48146479 | An adaptive confirmatory trial with interim treatment selection: practical experiences and unbalanced randomization |
| Q44262116 | An adaptive seamless phase II/III design for oncology trials with subpopulation selection using correlated survival endpoints |
| Q41339618 | An adaptive two-stage dose-response design method for establishing proof of concept |
| Q53281780 | Bias, Operational Bias, and Generalizability in Phase II/III Trials. |
| Q61810177 | Clinical trial design and new therapies for pulmonary arterial hypertension |
| Q36042202 | Closed Testing in Pharmaceutical Research: Historical and Recent Developments |
| Q47387422 | Comparison of design strategies for a three-arm clinical trial with time-to-event endpoint: Power, time-to-analysis, and operational aspects |
| Q42926272 | Conditionally unbiased estimation in phase II/III clinical trials with early stopping for futility |
| Q42268244 | Confidence intervals for confirmatory adaptive two-stage designs with treatment selection |
| Q30813133 | Data-driven treatment selection for seamless phase II/III trials incorporating early-outcome data |
| Q38660962 | Decision-theoretic designs for a series of trials with correlated treatment effects using the Sarmanov multivariate beta-binomial distribution. |
| Q35808427 | Design issues in randomized phase II/III trials |
| Q48152166 | Designing a seamless phase II/III clinical trial using early outcomes for treatment selection: an application in multiple sclerosis |
| Q38052914 | Designing studies to find early signals of efficacy |
| Q44628142 | Discussion of the article by Trippa, Rosner, and Müller on Bayesian enrichment strategies for randomized discontinuation trials |
| Q46029341 | Dose selection in seamless phase II/III clinical trials based on efficacy and safety. |
| Q41027668 | Estimation after subpopulation selection in adaptive seamless trials |
| Q38280824 | Flexible selection of a single treatment incorporating short-term endpoint information in a phase II/III clinical trial |
| Q39852504 | Group sequential designs with prospectively planned rules for subpopulation enrichment |
| Q44588751 | Group sequential enrichment design incorporating subgroup selection |
| Q37868491 | Group-sequential methods for adaptive seamless phase II/III clinical trials |
| Q57305862 | Innovative Approaches for Designing and Analyzing Adaptive Dose-Ranging Trials |
| Q38062520 | Integrated phase II/III clinical trials in oncology: a case study |
| Q37940788 | Integrating predictive biomarkers and classifiers into oncology clinical development programmes |
| Q42410759 | Interim analyses in diagnostic versus treatment studies: differences and similarities |
| Q46370855 | Interval estimation in two-stage, drop-the-losers clinical trials with flexible treatment selection |
| Q38652565 | Investigating interventions to increase uptake of HIV testing and linkage into care or prevention for male partners of pregnant women in antenatal clinics in Blantyre, Malawi: study protocol for a cluster randomised trial |
| Q43832289 | Many-to-one comparison after sample size reestimation for trials with multiple treatment arms and treatment selection |
| Q39896089 | Multiple testing procedures for adaptive enrichment designs: combining group sequential and reallocation approaches |
| Q45328879 | On Flexibility of Adaptive Designs and Criteria for Choosing A Good One—A Discussion of FDA Draft Guidance |
| Q51504861 | Optimal sample sizes for phase II clinical trials and pilot studies. |
| Q38675644 | Optimizing drug development in oncology by clinical trial simulation: Why and how? |
| Q30860286 | Optimizing the data combination rule for seamless phase II/III clinical trials |
| Q37481946 | PIPELINEs: Creating Comparable Clinical Knowledge Efficiently by Linking Trial Platforms |
| Q43853920 | Partition testing in confirmatory adaptive designs with structured objectives |
| Q43903604 | Perspectives on the Use of Adaptive Designs in Clinical Trials. Part I. Statistical Considerations and Issues |
| Q91943657 | Phase II Trials in Drug Development and Adaptive Trial Design |
| Q37523405 | Physiotherapy Rehabilitation for Osteoporotic Vertebral Fracture (PROVE): study protocol for a randomised controlled trial. |
| Q38636761 | Point estimation in adaptive enrichment designs |
| Q51397243 | Practical guidelines for adaptive seamless phase II/III clinical trials that use Bayesian methods. |
| Q57430633 | Refinement of the Clinical Scenario Evaluation Framework for Assessment of Competing Development Strategies with an Application to Multiple Sclerosis |
| Q44490906 | Regulatory perspectives on multiplicity in adaptive design clinical trials throughout a drug development program |
| Q34840765 | Sample size re-assessment leading to a raised sample size does not inflate type I error rate under mild conditions |
| Q37260022 | Seamless Phase IIa/IIb and enhanced dose-finding adaptive design |
| Q37781210 | Seamless phase II/III designs |
| Q52309328 | Sensitivity of adaptive enrichment trial designs to accrual rates, time to outcome measurement, and prognostic variables. |
| Q38459886 | Simple sequential boundaries for treatment selection in multi-armed randomized clinical trials with a control |
| Q62589002 | Some Characteristics of the Varying-Stage Adaptive Phase II/III Clinical Trial Design |
| Q40274973 | Testing multiple primary endpoints in clinical trials with sample size adaptation |
| Q90663624 | The future of clinical trials in urological oncology |
| Q51786270 | The future of drug development: advancing clinical trial design. |
| Q34473377 | Toxicologic pathology in the 21st century |
| Q34508470 | Traumeel vs. diclofenac for reducing pain and improving ankle mobility after acute ankle sprain: a multicentre, randomised, blinded, controlled and non-inferiority trial |
| Q38380750 | Twenty-five years of confirmatory adaptive designs: opportunities and pitfalls. |
| Q44216598 | Type I error rate control in adaptive designs for confirmatory clinical trials with treatment selection at interim |
| Q39831868 | Unbiased estimation in seamless phase II/III trials with unequal treatment effect variances and hypothesis-driven selection rules. |
| Q52646325 | Using Bayesian modeling in frequentist adaptive enrichment designs. |
Search more.